Aclaris Therapeutics Inc’s filing revealed that its Director Powell Andrew Kenneth William acquired Company’s shares for reported $7500.0 on Mar 04 ’24. In the deal valued at $1.25 per share,6,000 shares were bought. As a result of this transaction, Powell Andrew Kenneth William now holds 28,863 shares worth roughly $34346.97.
Then, Powell Andrew Kenneth William bought 8,500 shares, generating $10,455 in total proceeds. Upon buying the shares at $1.23, the Director now owns 22,863 shares.
Before that, Monahan Joseph sold 6,000 shares. Aclaris Therapeutics Inc shares valued at $30,460 were divested by the Chief Scientific Officer at a price of $5.08 per share. As a result of the transaction, Monahan Joseph now holds 129,724 shares, worth roughly $0.15 million.
H.C. Wainwright downgraded its Aclaris Therapeutics Inc [ACRS] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including William Blair’s analysts, who decreased its forecast for the stock in mid November from “an Outperform” to “a Mkt perform”. Evercore ISI began covering ACRS with “an Outperform” recommendation on October 03, 2023. Stifel started covering the stock on December 14, 2022. It rated ACRS as “a Buy”.
Price Performance Review of ACRS
On Friday, Aclaris Therapeutics Inc [NASDAQ:ACRS] saw its stock fall -3.25% to $1.19. Over the last five days, the stock has lost -4.03%. Aclaris Therapeutics Inc shares have risen nearly 13.33% since the year began. Nevertheless, the stocks have fallen -86.27% over the past one year. While a 52-week high of $11.12 was reached on 03/06/24, a 52-week low of $0.59 was recorded on 01/12/24. SMA at 50 days reached $1.2150, while 200 days put it at $4.4548. A total of 0.53 million shares were traded, compared to the trading of 0.73 million shares in the previous session.
Levels Of Support And Resistance For ACRS Stock
The 24-hour chart illustrates a support level at 1.1710, which if violated will result in even more drops to 1.1520. On the upside, there is a resistance level at 1.2220. A further resistance level may holdings at 1.2540. The Relative Strength Index (RSI) on the 14-day chart is 47.02, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0212, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 65.00%. Stochastics %K at 52.94% indicates the stock is a holding.
How much short interest is there in Aclaris Therapeutics Inc?
A steep rise in short interest was recorded in Aclaris Therapeutics Inc stocks on Mar 15, 2024, dropping by -0.71 million shares to a total of 5.12 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 5.83 million shares. There was a decline of -13.87%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 8.32% of the overall stock float, the days-to-cover ratio (short ratio) fell to 3.55.
The most recent change occurred on December 01, 2022 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $25 price target.
